The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, phase 1 trial with expansion cohort of botensilimab (AGEN1181) + balstilimab (AGEN2034) + nab-paclitaxel + gemcitabine + cisplatin + chloroquine + celecoxib in adult patients with previously untreated metastatic pancreatic cancer.
 
Erkut Borazanci
Consulting or Advisory Role - Arcus Biosciences; BPGbio; ClearNote Health; Corcept Therapeutics; Merus; NanOlogy; VCN Biosciences
Research Funding - BioNTech (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Helix BioPharma (Inst); Idera (Inst); Lilly (Inst); Merck (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst)
 
Gayle Jameson
No Relationships to Disclose
 
Brandi Carter
No Relationships to Disclose
 
Lu Zhao
No Relationships to Disclose
 
Haiyong Han
Employment - CVS Health (I)
Stock and Other Ownership Interests - CVS Health; ImproveBio; Stromatis Pharma
Consulting or Advisory Role - ImproveBio; Stromatis Pharma
Research Funding - Avicenna Biosciences (Inst); Exact Therapeutics (Inst); Minneamrita Therapeutics (Inst)
 
Derek Cridebring
No Relationships to Disclose
 
Michael Gordon
Stock and Other Ownership Interests - Sphinx HS (previously CAREMISSION)
Consulting or Advisory Role - Deciphera; Imaging Endpoints; Morphic Therapeutic; OnQuality Pharmaceuticals; Qualigen Therapeutics; SpringWorks Therapeutics; Viracta Therapeutics
Research Funding - Abbvie (Inst); Agenus (Inst); Arcus Biosciences (Inst); Corcept Therapeutics (Inst); Deciphera (Inst); DynamiCure Biotechnology (Inst); Fore Biotherapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); ImaginAb (Inst); Merck Serono (Inst); NiKang Therapeutics (Inst); Nimbus Therapeutics (Inst); Novartis (Inst); OncoResponse (Inst); Pfizer (Inst); Pionyr (Inst); Plexxikon (Inst); Pyxis (Inst); Revolution Medicines (Inst); Riboscience (Inst); Shenzen Ionova (Inst); Sirnaomics (Inst); SQZ Biotech (Inst); Syndax (Inst); Theseus Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Veru (Inst)
Patents, Royalties, Other Intellectual Property - Application Serial No.: PCT/US24/27766 Filing Date: May 3, 2024 Title: Planet atmosphere gases enwrapped into composite nanomaterials with medical treatment applications
 
Daniel Von Hoff
Stock and Other Ownership Interests - (3+2) Pharma; AADi; AcuViz; Anthem Inc; CerRx; Halia Therapeutics; Lycia Therapeutics; Medtronic; Origin Commercial Advisors; Orpheus Bioscience; Stingray Therapeutics; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Consulting or Advisory Role - AiMed; AlaMab Therapeutics; Autonomix; Bryologyx; CanBas; Catamaran Bio; Compass Therapeutics; Coordination Pharmaceuticals; Crinetics Pharmaceuticals; CyMon Bio; Diakonos Research; Econic Biosciences; EnGeneIC; Erimos Pharmaceuticals; EXACT Therapeutics; ImaginAb; Imaging Endpoints; ImmuneOncia; Immunophotonics; Improve Bio; Indaptus fka Decoy; Invios GmbH; Lixte Biotechnology; Lycia Therapeutics; Mekanistic Therapeutics; Moleculin Biotech; Novita Pharmaceuticals; Oncology Venture; Orphagen Pharmaceuticals; Panavance Therapeutics fka Geistlich; Peptomyc; Pfizer; Phosplatin Therapeutics; POINT Biopharma; Race Oncology; Red Arrow Therapeutics; Remix Therapeutics; Remunity; Sellas Life Sciences; SignaBlok; Sirnaomics; SIWA Therapeutics; SMP Oncology fka SDP/Tolero; Soley Therapeutics; SOTIO; TD2; Vicus Therapeutics; Viracta Therapeutics; Xenthera; Xerient
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Samumed (Inst); Strategia (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer